Sangamo Asset Turnover vs Total Assets Per Share Analysis

SGMO Stock  USD 0.62  0.02  3.33%   
Trend analysis of Sangamo Therapeutics balance sheet accounts such as Liabilities And Stockholders Equity of 218.1 M, Other Stockholder Equity of 1.6 B, Total Liabilities of 73.5 M or Short Long Term Debt Total of 30 M provides information on Sangamo Therapeutics' total assets, liabilities, and equity, which is the actual value of Sangamo Therapeutics to its prevalent stockholders. By breaking down trends over time using Sangamo Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

About Sangamo Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Sangamo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Sangamo Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Sangamo Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Sangamo currently owns. An asset can also be divided into two categories, current and non-current.

Sangamo Therapeutics Balance Sheet Chart

Sangamo Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Sangamo Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Sangamo Therapeutics' Accounts Payable is very stable compared to the past year. As of the 28th of March 2024, Non Currrent Assets Other is likely to grow to about 17.5 M, though Retained Earnings are likely to grow to (1.3 B).

Total Assets

Total assets refers to the total amount of Sangamo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sangamo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.
Most indicators from Sangamo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.As of the 28th of March 2024, Selling General Administrative is likely to grow to about 64.2 M, though Tax Provision is likely to grow to (4.3 M).
 2021 2022 2023 2024 (projected)
Gross Profit110.7M111.3M154.0M161.7M
Total Revenue110.7M111.3M176.2M185.0M

Sangamo Therapeutics fundamental ratios Correlations

0.97-0.40.890.530.620.970.80.730.950.910.420.890.940.360.960.410.060.890.970.750.970.03-0.780.630.51
0.97-0.310.810.460.560.890.730.640.860.840.320.830.880.250.960.54-0.060.910.90.650.97-0.1-0.740.50.42
-0.4-0.31-0.41-0.98-0.96-0.48-0.79-0.86-0.56-0.6-0.87-0.46-0.51-0.96-0.220.0-0.13-0.11-0.45-0.84-0.32-0.220.19-0.88-0.86
0.890.81-0.410.490.580.920.80.710.930.940.520.830.950.380.790.310.230.690.90.80.790.19-0.720.730.46
0.530.46-0.980.490.990.580.840.890.650.670.860.560.610.930.370.080.060.260.560.880.460.14-0.290.890.86
0.620.56-0.960.580.990.660.890.930.730.760.850.640.690.910.460.150.090.350.640.920.550.16-0.370.910.87
0.970.89-0.480.920.580.660.840.790.990.930.510.890.950.460.920.260.180.821.00.810.920.16-0.780.730.57
0.80.73-0.790.80.840.890.840.930.880.930.690.780.870.770.650.350.220.540.820.960.710.25-0.530.870.8
0.730.64-0.860.710.890.930.790.930.830.860.750.770.770.870.570.110.240.470.770.950.670.28-0.540.90.93
0.950.86-0.560.930.650.730.990.880.830.950.590.90.960.540.880.220.180.770.970.860.880.17-0.770.80.63
0.910.84-0.60.940.670.760.930.930.860.950.610.870.970.570.780.390.240.660.910.920.80.23-0.690.820.67
0.420.32-0.870.520.860.850.510.690.750.590.610.390.560.830.23-0.020.220.150.480.810.310.28-0.150.90.69
0.890.83-0.460.830.560.640.890.780.770.90.870.390.880.450.830.170.080.670.880.760.830.07-0.940.680.62
0.940.88-0.510.950.610.690.950.870.770.960.970.560.880.480.830.40.20.70.940.870.840.18-0.740.770.58
0.360.25-0.960.380.930.910.460.770.870.540.570.830.450.480.17-0.110.310.060.450.830.280.4-0.180.870.91
0.960.96-0.220.790.370.460.920.650.570.880.780.230.830.830.170.37-0.050.960.920.560.98-0.09-0.780.450.33
0.410.540.00.310.080.150.260.350.110.220.39-0.020.170.4-0.110.37-0.10.410.270.230.39-0.13-0.06-0.01-0.04
0.06-0.06-0.130.230.060.090.180.220.240.180.240.220.080.20.31-0.05-0.1-0.090.190.3-0.020.99-0.030.330.24
0.890.91-0.110.690.260.350.820.540.470.770.660.150.670.70.060.960.41-0.090.830.420.95-0.14-0.620.30.23
0.970.9-0.450.90.560.641.00.820.770.970.910.480.880.940.450.920.270.190.830.790.930.16-0.770.710.55
0.750.65-0.840.80.880.920.810.960.950.860.920.810.760.870.830.560.230.30.420.790.630.34-0.530.960.84
0.970.97-0.320.790.460.550.920.710.670.880.80.310.830.840.280.980.39-0.020.950.930.63-0.05-0.750.510.44
0.03-0.1-0.220.190.140.160.160.250.280.170.230.280.070.180.4-0.09-0.130.99-0.140.160.34-0.050.010.370.31
-0.78-0.740.19-0.72-0.29-0.37-0.78-0.53-0.54-0.77-0.69-0.15-0.94-0.74-0.18-0.78-0.06-0.03-0.62-0.77-0.53-0.750.01-0.46-0.4
0.630.5-0.880.730.890.910.730.870.90.80.820.90.680.770.870.45-0.010.330.30.710.960.510.37-0.460.81
0.510.42-0.860.460.860.870.570.80.930.630.670.690.620.580.910.33-0.040.240.230.550.840.440.31-0.40.81
Click cells to compare fundamentals

Sangamo Therapeutics Account Relationship Matchups

Sangamo Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets637.5M938.6M721.9M562.5M165.3M218.1M
Total Stockholder Equity432.7M497.4M375.3M295.0M82.9M144.6M
Retained Earnings(657.0M)(778.0M)(956.3M)(1.1B)(1.4B)(1.3B)
Other Assets10.6M15.1M16.8M18.5M1.00.95
Common Stock Shares Outstanding112.1M134.4M144.6M154.3M174.4M183.2M
Liabilities And Stockholders Equity637.5M938.6M721.9M562.5M165.3M218.1M
Other Stockholder Equity1.1B1.3B1.3B1.5B1.5B1.6B
Total Liab204.8M441.2M346.6M267.6M82.4M73.5M
Short Long Term Debt Total44.4M42.1M48.1M43.1M38.1M30.0M
Other Current Liab21.3M30.7M28.4M33.4M27.9M29.3M
Total Current Liabilities69.9M143.5M127.9M111.7M47.7M34.0M
Property Plant And Equipment Net107.2M112.4M124.7M125.5M52.9M29.2M
Accounts Payable6.7M12.6M9.8M22.4M15.3M16.0M
Cash80.4M131.3M178.9M100.4M45.2M45.0M
Non Current Assets Total232.0M278.9M323.2M262.2M71.0M68.1M
Non Currrent Assets Other4.0M7.9M10.2M12.3M16.6M17.5M
Cash And Short Term Investments385.0M692.0M464.7M277.6M81.0M77.0M
Net Receivables37.6M6.3M6.4M4.5M1.3M1.3M
Common Stock Total Equity1.2M1.4M1.5M1.7M1.5M1.4M
Short Term Investments282.0M510.1M197.7M177.2M35.8M34.0M
Non Current Liabilities Total134.9M297.6M218.7M155.8M34.7M57.7M
Property Plant And Equipment Gross107.2M112.4M149.7M162.1M103.9M109.1M
Total Current Assets405.5M659.7M398.8M300.3M94.3M175.7M
Accumulated Other Comprehensive Income(2.4M)5.4M(4.0M)(8.4M)(4.6M)(4.4M)
Common Stock1.2M1.4M1.5M1.7M1.8M1.7M
Net Debt(36.0M)(89.2M)(130.8M)(57.3M)(7.1M)(7.5M)
Other Current Assets5.4M12.0M15.9M18.2M12M12.6M
Property Plant Equipment29.9M41.3M51.5M63.5M73.1M76.7M
Current Deferred Revenue38.7M96.6M85.7M51.8M59.5M62.5M
Intangible Assets53.2M58.1M53.8M50.7M58.3M61.3M
Other Liab93.7M259.2M174.6M116.9M134.4M141.1M
Net Tangible Assets340.1M397.3M281.9M206.7M237.7M227.0M
Retained Earnings Total Equity(657.0M)(778.0M)(956.3M)(1.1B)(1.0B)(982.0M)
Capital Surpluse1.1B1.3B1.3B1.5B1.7B873.1M
Inventory(22.5M)(50.5M)(88.2M)1.00.90.95
Deferred Long Term Liab6.6M7.2M6.6M6.3M7.2M9.3M
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sangamo Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sangamo Therapeutics' short interest history, or implied volatility extrapolated from Sangamo Therapeutics options trading.

Currently Active Assets on Macroaxis

When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Sangamo Stock analysis

When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.48)
Revenue Per Share
1.01
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.18)
Return On Equity
(1.36)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.